The WinFood Intervention Study: the effects of improved complementary foods on nutrition and health among Cambodian infants and children

Conditions

Infants at risk of undernutrition Nutritional, Metabolic, Endocrine Infants at risk of undernutrition

Jutta Kloppenborg Heick Skau, Benedikte Grenov, Chhoun Chamnan, Mary Chea, Frank T. Wieringa et al. (13 authors)

British Journal Of Nutrition2019-01-2325 citations

Effects of animal source food and micronutrient fortification in complementary food products on body composition, iron status, and linear growth: a randomized trial in Cambodia.

Skau JK, Touch B, Chhoun C, Chea M, Unni US, Makurat J, Filteau S, Wieringa FT, Dijkhuizen MA, Ritz C, Wells JC, Berger J, Friis H, Michaelsen KF, Roos N.

2015-01-2853 citations

10.3945/ajcn.114.084889

The use of linear programming to determine whether a formulated complementary food product can ensure adequate nutrients for 6- to 11-month-old Cambodian infants.

Skau JK, Bunthang T, Chamnan C, Wieringa FT, Dijkhuizen MA, Roos N, Ferguson EL.

2013-10-2361 citations

10.3945/ajcn.113.073700

Interventions

Four different pre-cooked complementary food supplements given as a porridge daily from 6-15 months of age (6-8 months: 50 g, 9-12 months: 75 g, 13-15 months: 125 g) 1. WinFood CF: rice and two highly

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children who are 6 months old and have a weight-for-height z-score > -3

Exclusion criteria

Exclusion criteria: 1. Weight-for-height z-score < -3 2. Bilateral pitting oedema 3. Haemoglobin (Hb) < 80 g/L 4. Clinical signs of vitamin A deficiency (xerosis or Bitot spots). These children will be referred for treatment.

Design outcomes

Primary

Measure	Time frame
Changes in fat-free body mass (deuterium dilution) and iron status (serum ferritin and transferrin receptors) from baseline (age 6 months) until the end of the 9 month intervention	—

Secondary

Measure	Time frame
Changes in: 1. Ponderal and linear growth 2. Physical activity (using an accelerometer, actigraph) 3. Motor milestones (questionnaire, clinic visits) 4. Morbidity 5. Haemoglobin concentration (using Haemocue) 6. Serum concentrations of acute phase proteins [C-reactive protein (CRP) and a-acid glycoprotein(AGP)], insulin-like growth factor (IGF)-1 and zinc 7. Whole blood fatty acid composition Measured from baseline (age 6 months) until the end of the 9 month intervention	—

Measure

Time frame

Changes in: 1. Ponderal and linear growth 2. Physical activity (using an accelerometer, actigraph) 3. Motor milestones (questionnaire, clinic visits) 4. Morbidity 5. Haemoglobin concentration (using Haemocue) 6. Serum concentrations of acute phase proteins [C-reactive protein (CRP) and a-acid glycoprotein(AGP)], insulin-like growth factor (IGF)-1 and zinc 7. Whole blood fatty acid composition Measured from baseline (age 6 months) until the end of the 9 month intervention

—

Countries

Cambodia

Outcome results

None listed